Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation by unknown
RESEARCH ARTICLE Open Access
Casitas B-lineage lymphoma linker helix
mutations found in myeloproliferative
neoplasms affect conformation
Lori Buetow1, Giancarlo Tria2,4, Syed Feroj Ahmed1, Andreas Hock1, Hao Dou1,3, Gary J. Sibbet1,
Dmitri I. Svergun2 and Danny T. Huang1*
Abstract
Background: Casitas B-lineage lymphoma (Cbl or c-Cbl) is a RING ubiquitin ligase that negatively regulates protein
tyrosine kinase (PTK) signalling. Phosphorylation of a conserved residue (Tyr371) on the linker helix region (LHR)
between the substrate-binding and RING domains is required to ubiquitinate PTKs, thereby flagging them for
degradation. This conserved Tyr is a mutational hotspot in myeloproliferative neoplasms. Previous studies have
revealed that select point mutations in Tyr371 can potentiate transformation in cells and mice but not all possible
mutations do so. To trigger oncogenic potential, Cbl Tyr371 mutants must perturb the LHR-substrate-binding
domain interaction and eliminate PTK ubiquitination. Although structures of native and pTyr371-Cbl are available,
they do not reveal how Tyr371 mutations affect Cbl’s conformation. Here, we investigate how Tyr371 mutations
affect Cbl’s conformation in solution and how this relates to Cbl’s ability to potentiate transformation in cells.
Results: To explore how Tyr371 mutations affect Cbl’s properties, we used surface plasmon resonance to measure
Cbl mutant binding affinities for E2 conjugated with ubiquitin (E2–Ub), small angle X-ray scattering studies to
investigate Cbl mutant conformation in solution and focus formation assays to assay Cbl mutant transformation
potential in cells. Cbl Tyr371 mutants enhance E2–Ub binding and cause Cbl to adopt extended conformations
in solution. LHR flexibility, RING domain accessibility and transformation potential are associated with the extent
of LHR-substrate-binding domain perturbation affected by the chemical nature of the mutation. More disruptive
mutants like Cbl Y371D or Y371S are more extended and the RING domain is more accessible, whereas Cbl Y371F
mimics native Cbl in solution. Correspondingly, the only Tyr371 mutants that potentiate transformation in cells are
those that perturb the LHR-substrate-binding domain interaction.
Conclusions: c-Cbl’s LHR mutations are only oncogenic when they disrupt the native state and fail to ubiquitinate
PTKs. These findings provide new insights into how LHR mutations deregulate c-Cbl.
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Background
Dysregulated signalling is a prominent feature in cellular
transformation and tumorigenesis. The proto-oncogene
Casitas B-lineage lymphoma (Cbl or c-Cbl), encodes an
E3 ubiquitin ligase that downregulates PTK-directed cell
signaling through ubiquitination, thereby targeting these
kinases for lysosomal or proteasomal degradation [1, 2].
Cbl is a member of the Cbl family of proteins, so charac-
terized based on a highly conserved N-terminal region
that contains the structural components required for
ubiquitin ligase activity. In simpler eukaryotic organisms,
such as Caenorhabditis elegans and Dictyostelium discoi-
deum, only one Cbl protein is present, but in mammals
there are three, including Cbl, Cbl-b and Cbl-c.
The conserved N-terminus of Cbl family proteins con-
tains a substrate tyrosine kinase-binding domain (TKBD),
a linker helix region (LHR) and a RING domain (Fig. 1a).
The TKBD confers specificity to Cbl’s ligase activity based
on the selective recruitment of phosphorylated sub-
strates containing an (N/D)XpY(S/T)XXP, DpYR or
RA(V/I)XNQpY(S/T) motif [3]. The RING domain mediates
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Fig. 1 Model depicting linker helix (LH)-mediated regulation of Cbl ligase. a Domains of Cbl’s N-terminal ubiquitin ligase region. A blue rectangle
and navy wavy line correspondingly depict the TKBD and its substrate-binding site. The LHR and its components are indicated with LL1 coloured
purple, LL2 green and LH yellow. A yellow hexagon depicts the LH Tyr. The RING is coloured orange with the two loops representing the E2-
binding site. b Model of unphosphorylated Cbl coloured as in (a). When Tyr371 is unphosphorylated, the LH is clamped to the TKBD and move-
ment of the RING restricted to the TKBD face opposing the substrate-binding site. Rotation about LL2 allows Cbl to fluctuate between an autoin-
hibited state where the E2-binding site is occluded (left) and a catalytically competent state where E2 is able to bind (right). c Model of
phosphorylated Cbl coloured as in (a). A brown hexagon and circle represent the phosphorylated LH Tyr. When Tyr371 is phosphorylated, the
LH clamps into the RING domain and LL1 rotates 180°, juxtaposing the RING domain and substrate-binding face of the TKBD. The Tyr371 binding
site on the TKBD cannot accommodate a phosphate moiety, thereby eliminating the LH-TKBD interaction. Whether the RING domain is flexible
in solution is unknown. d Model depicting possible states of Cbl Tyr 371 mutants coloured as in (a). The LH Tyr371 mutant is shown as an X in
a red square. Cbl Y371X mutants are predicted to favour different states depending on the chemical nature of the substitution. Less disruptive
mutants are expected to maintain the unphosphorylated equilibrium (left and middle), whereas more disruptive mutants are expected to perturb
the LH-TKBD interaction, leaving the RING in an open, catalytically competent conformation with greater access to space surrounding the TKBD (right)
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enzyme to the substrate [4, 5]. Within the LHR is a
conserved tyrosine (Tyr371 in Cbl) that is crucial for
regulating ligase activity. Phosphorylation of this tyro-
sine enhances ligase activity and is essential for ubiqui-
tination of receptor PTKs [6–11]. In addition to the
highly conserved N-terminus, Cbl and Cbl-b also have
extensive C-termini that confer adaptor-like functions
to these proteins based on the ability to mediate mul-
tiple protein-protein interactions. These include a pro-
line rich region that mediates interactions with SH3
domain-containing proteins and a tyrosine rich region
that, upon phosphorylation, becomes a binding motif
for other SH2 domain-containing proteins [12]. Cbl
and Cbl-b terminate with an ubiquitin-associated do-
main, which is crucial for homo- and heterodimeriza-
tion of these two Cbl proteins [13, 14].
Cbl abnormalities are associated with a number of
human cancers. High expression of Cbl is commonly
observed in several human breast cancer cell lines as
well as primary breast and prostate cancer tissues [15, 16].
In addition, Cbl mutations are observed in myelodysplas-
tic syndromes-myeloproliferative neoplasms (MDS/MPN)
and non-small cell lung cancers [17, 18]. Cbl is suggested
to have different roles in pathological processes depending
on its function as a ligase or adaptor. Breast and prostate
cancer cell line oncogenic characteristics are reduced
when Cbl is knocked down, and, in breast cancer cells,
independent of its ligase activity, Cbl mediates suppres-
sion of transcriptional activity induced by the tumour
suppressor transforming growth factor-β1 [15, 16]. In
contrast, more in-depth studies of select MDS/MPN mu-
tants suggest that these mutants potentiate transformation
because they fail to ubiquitinate and thereby downregulate
PTK signalling [19, 20].
The highest frequency of missense mutations in MDS/
MPN clinical samples occurs at Tyr371; identified muta-
tions include Cbl Y371S, Y371H, Y371C, and Y371D. Cbl
Y371S and Y371H have been investigated extensively in
independent studies [19, 20]. Cbl Y371S promotes colony
formation in soft-agar assays and induces tumour forma-
tion when injected into nude mice. Likewise, Cbl Y371H
promotes cytokine-independent growth in cells but only
when endogenous Cbl is knocked down. Both display
defects in their ability to ubiquitinate the PTK EGFR.
For Tyr371 mutations in the LHR, although defective
PTK ubiquitination contributes to aberrant cell signal-
ling, it is not sufficient to potentiate transformation.
Cbl Y371F shows reduced EGFR ubiquitination in vitro
and in cells [6, 21], but it is significantly less efficient in
promoting colony formation in soft agar assays and
does not induce tumour formation when injected into
mice [21, 22].
A number of factors contribute to how phosphoryl-
ation of Tyr371 regulates Cbl’s ligase activity. In the
unphosphorylated state, Cbl’s RING domain rotates be-
tween an open, catalytically competent conformation
and a closed conformation (Fig. 1b) [5, 6]. In the closed
conformation, the E2-binding site on the RING domain
is occluded and Cbl is autoinhibited. Although the RING
can bind E2 thioesterified with Ub (E2 ~Ub; ~ indicates
thioester bond) in the unphosphorylated state, the
RING domain is restricted to the TKBD face opposite
the substrate-binding site by interactions between the
LHR and TKBD. The LHR comprises a long loop
(called linker loop 1 or LL1, residues 353–363) followed
by an α-helix (LH, residues 364–374) and then a sec-
ond shorter loop (LL2, residues 375–380). Tyr371 is on
the LH, and, in the unphosphorylated state, Tyr371 and
several other residues from the LH, including Tyr368, bind
to the TKBD, limiting movement between the RING and
TKBD to rotation about LL2. Phosphorylation of Tyr371
eliminates this LHR-TKBD interaction – modelling
suggests the Tyr371 binding pocket on the TKBD is too
small to accommodate a phosphate group. Instead,
pTyr371-LHR forms a new set of interactions with the
RING domain that stabilizes E2 ~ Ub during Ub trans-
fer [6, 7]. Movement within LL2 is more restricted by
this new set of interactions but a conformational
change in LL1 juxtaposes the RING domain with the
substrate-binding face of the TKBD (Fig. 1c). In so-
lution, whether LL1 is flexible and adopts multiple
conformations or prefers the crystallographically ob-
served conformation where the RING is juxtaposed
with the substrate binding face of the TKBD is
unclear.
We postulate that Y371 mutations might have differ-
ent oncogenic potentials due to flexibility differences in
Cbl’s linker region mediated by the LHR-TKBD inter-
action (Fig. 1d). We predict that, while a large aromatic
residue like Phe cannot duplicate the Tyr371-TKBD inter-
actions, neither will it perturb those interactions; hence,
Cbl Y371F can adopt and readily maintain conformations
observed in the unphosphorylated state. On the other
hand, mutations, such as Y371S, introduce a polar residue
into a hydrophobic pocket and are likely to perturb or
occlude the LH-TKBD interaction, thereby unlocking the
LHR from the TKBD and leaving Cbl in an intermediate
activity state where the E2 ~Ub binding site on the RING
domain is exposed but lacking the pTyr371-LHR E2 ~Ub
stabilizing component (Fig. 1c,d). To investigate the in-
fluence of mutations and phosphorylation on Cbl’s LHR
flexibility and RING accessibility in solution, we per-
formed small-angle X-ray scattering (SAXS) analysis and
surface plasmon resonance (SPR) assays on pTyr371-Cbl,
unphosphorylated Cbl and a selection of Cbl variants.
We then performed focus formation assays to explore
the relationship between this flexibility and oncogenic
potential.
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Results
Cbl’s LHR-TKBD interactions affect RING binding affinity
for E2 ~ Ub
Previous studies suggest Cbl Y371 mutants have the
potential to perturb or abrogate LHR-E2 interactions
essential for ligase activity [5, 21]. To investigate this
possibility, we used SPR to measure binding of the sub-
strate E2 UbcH5B conjugated to Ub (UbcH5B–Ub;
hyphen indicates a non-hydrolyzable amide linkage) to
variants of the N-terminal fragment of Cbl comprising
the TKBD, linker region and RING domain (N-Cbl,
residues 47–435), as performed previously [6, 23]. We
tested the unphosphorylated N-Cbl variants containing
the Tyr371 mutations identified in MDS/MPN clinical
samples as well as N-Cbl Y371A, which behaves similarly
to the MDS/MPN Tyr371 mutants [21], and N-Cbl Y371F
based on its reduced transformation potential in cells and
mice. In addition, we tested Cbl Y371E, which has previ-
ously been shown to stimulate Cbl activity in vitro [8].
N-Cbl Y368F was also included in our assays because
this mutation is required to generate homogeneously
phosphorylated pTyr371-N-Cbl; previous studies dem-
onstrate this mutation does not affect the structure or
ligase activity in vitro or in cells [6, 21, 22]. We also
included N-Cbl M222E, which disrupts the closed con-
formation without perturbing the TKDB-LHR interaction
[6], so that we could investigate changes induced by rota-
tion about LL2. We predicted that, if the RING domain
were unfolded, no binding of UbcH5B–Ub to N-Cbl Y371
variants is expected, whereas, if these variants simply
weaken the LHR-TKBD interaction, Cbl Y371 mutants
will adopt the closed conformation less frequently and
thus bind UbcH5B–Ub more tightly than wild-type N-
Cbl. None of the N-Cbl Y371 mutants is expected to
bind UbcH5B–Ub as tightly as pTyr371-N-Cbl because
pTyr371 eliminates the closed, autoinhibited conformation
and forms additional interactions with UbcH5B ~Ub. All
of the N-Cbl variants in our SPR assay bind
UbcH5B–Ub with similar or higher affinity than wild-
type N-Cbl (84 μM) but more weakly than pTyr371-
N-Cbl (2.6 μM, Table 1), suggesting mutations in the
LHR do not affect the competency of the RING do-
main to bind UbcH5B–Ub. Other mutations in the
LHR also affect LHR-TKBD interactions as evidenced
by the higher binding affinity of N-Cbl Y368F
(49 μM) for UbcH5B–Ub than wild-type N-Cbl.
The SPR data demonstrate that the chemical charac-
teristics of the side chain of the mutated amino acid in
the N-Cbl Y371 variants influence binding affinity for
UbcH5B–Ub: the greater potential the mutation has to
perturb the Tyr371 binding pocket on the TKBD, the
higher the binding affinity for UbcH5B–Ub. The highest
binding affinities are observed when Tyr is substituted
with an amino acid that has a shorter, non-aromatic and
polar or charged side chain like N-Cbl Y371S (16 μM),
Y371E (9 μM), and Y371D (10 μM); the binding affin-
ities of these mutants are comparable to N-Cbl M222E
(14 μM), which disrupts the RING-TKBD interaction in
the closed, autoinhibited conformation. In contrast, when
Tyr371 is substituted with Phe, the UbcH5B–Ub binding
affinity is comparable to wild-type (N-Cbl Y371F, 84 μM)
and the LHR-TKBD interaction is unperturbed, as demon-
strated by the crystallographic structure of N-Cbl Y371F
(Additional file 1: Figure S1, Table S1). For the remaining
MDS/MPN mutants, polar and aromatic or short and
hydrophobic amino acids are substituted for Tyr371 (N-
Cbl Y371H, Y371A and Y371C). These are expected to
weaken the interactions within the Tyr371 binding pocket
but not as effectively as the group of mutants with short
and polar or charged side chains. Thus, the UbcH5B–Ub
binding affinity of these mutants is expected to fall be-
tween wild-type and the more disruptive mutants and this
is indeed what we observe in our SPR assays: N-Cbl
Y371H (39 μM), Y371A (30 μM) and Y371C (36 μM).
Characterization of wild-type and pTyr371 Cbl by SAXS
Initially, we sought to investigate how Tyr371 phosphoryl-
ation affects the conformation of Cbl in solution by per-
forming SAXS analysis on pTyr371-N-Cbl and wild-type
N-Cbl. The monomeric state of these N-Cbl variants was
confirmed by the SAXS-derived overall parameters (Fig. 2,
Table 2, Additional file 1: Table S2) and gel filtration chro-
matography (data not shown). The deduced molecular
masses (MMs) ranged from 41 to 48 kDa and are compar-
able with a predicted monomer mass of ~45 kDa for
N-Cbl.
The SAXS-derived radius of gyration (Rg) of wild-type
N-Cbl variant is ~2.4 nm whereas pTyr371-N-Cbl is
~2.8 nm, and the calculated maximum particle distances
(Dmax) are ~7.0 and ~9.2 nm, respectively. These differences
Table 1 Dissociation constants (Kd) for interactions between Cbl
variants and UbcH5B–Ub
Immobilized GST-Cbl variant Analyte Kd (μM)
WT UbcH5B–Ub 84 ± 2
Y371F UbcH5B–Ub 84 ± 2
Y371H UbcH5B–Ub 39 ± 1
Y371C UbcH5B–Ub 36 ± 1
Y371A UbcH5B–Ub 30 ± 1
Y371S UbcH5B–Ub 16 ± 0.7
Y371D UbcH5B–Ub 10 ± 0.5
Y371E UbcH5B–Ub 9 ± 0.4
pY371 Y368F UbcH5B–Ub 2.6 ± 0.6
Y368F UbcH5B–Ub 49 ± 2
M222E UbcH5B–Ub 14 ± 0.6
Standard errors of the mean are indicated
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indicate significant conformational changes in N-Cbl upon
phosphorylation of Tyr371. The presence of an extended tail
in the P(r) function of pTyr371-N-Cbl (Fig. 2b, Additional
file 1: Figure S2) suggests rearrangements of the RING do-
main that make the particle more elongated as compared to
the native one. In addition, the normalized Kratky plots
(Fig. 2c) for wild-type and pTyr371-N-Cbl demonstrate sig-
nificant differences. The wild-type reveals the peak at s Rg ≈
√3, as expected for globular particles [24], whereas for
pTyr371-N-Cbl the peak position is significantly shifted sug-
gesting the presence of structural disorder.
Fig. 2 SAXS analysis of wild-type (WT) and pTyr371-N-Cbl. a Top: WT experimental scattering data (dark red) versus theoretical scattering
curve from crystal structure (PDB:2Y1M) before (dashed green line; χ = 2.05) and after normal modes refinement (solid red line; χ = 0.94).
Bottom: pTyr371-N-Cbl experimental scattering data (orange) versus theoretical scattering from the EOM 2.0 ensemble (orange line; χ = 0.77). b P(r)
distribution of WT (solid red) and pTyr371-N-Cbl (dashed orange). c Normalized Kratky plot of WT and pTyr371-N-Cbl coloured as in (a). d EOM 2.0
distributions of the random pool (black) and the ensembles of WT and pTyr371-N-Cbl coloured as in (b)
Table 2 SAXS parameters for wild-type N-Cbl and pTyr371-N-Cbl
Parameter Wild-type pTyr371
Rg [P(r)] 2.4 nm 2.8 nm
Rg [Guinier] 2.4 nm 2.8 nm





MMPorod 43 kDa 46 kDa
MMDammif 44 kDa 47 kDa
Rg radius of gyration, Dmax maximum particle distances, V volume, MMmolecular mass
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The theoretical scattering computed from the native,
unphosphorylated crystal structure (PDB:2Y1M) gives
an overall reasonable fit to the experimental data but
also displays some systematic deviations (Fig. 2a). These
deviations point to possible differences between solu-
tion and crystalline states of the native protein. The
crystal structure was therefore refined using an iterative
normal mode analysis [25]. This procedure yielded a
model which was similar to the original structure (root
mean square deviation 1.015 Å) and provided a significant
improvement of the fit from χ = 2.05 to 0.95. Ab initio
shape reconstruction further confirms the globular state
of unphosphorylated Cbl (Fig. 3, Additional file 1:
Figure S3).
Given the expected flexibility of pTyr371-N-Cbl,
structural modelling was performed using an Ensemble
Optimization Method (EOM) [45]. Here, ensembles of
models with variable conformations are selected from a
pool of randomly generated models such that the scat-
tering from the ensemble fits the experimental data,
and the distributions of the overall parameters (e.g. Rg)
in the selected pool are compared to the original pool.
As a negative control, EOM was first used on the data
from N-Cbl and the selected ensembles showed predom-
inantly compact conformations (Fig. 2d). In contrast, the
selected ensembles for pTyr371-N-Cbl displayed broader
distributions of predominantly extended conformations,
which were on average more extended than the random
pool (Fig. 2d). These data indicate that pTyr371-N-Cbl is
extended and flexible in solution, suggesting that phos-
phorylation of the LH allows the RING domain to adopt
multiple conformations in solution and access multiple
surfaces of the TKBD (Fig. 4).
Characterization of N-Cbl mutants by SAXS
To study how LHR-TKBD interactions influence the flexi-
bility of LL1 in solution, we performed SAXS on a con-
centration series of our N-Cbl Tyr371 mutants, N-Cbl
Y368F and N-Cbl M222E. The monomeric state of all
N-Cbl variants was confirmed by the SAXS-derived
overall parameters (Additional file 1: Table S2) and gel
filtration chromatography (data not shown) with the ex-
ception of N-Cbl Y371C, where strong concentration-
dependent effects were observed; for this reason, N-Cbl
Y371C was omitted from further SAXS analysis. For the
remaining N-Cbl variants, the deduced MMs ranged from
41 to 48 kDa pointing to a monomeric state in solution.
Comparison of the SAXS-derived parameters as well
as quantification of the flexibility (Rflex) estimated by
using EOM revealed a link between the conformation of
N-Cbl in solution and the extent of perturbation of the
Tyr371-TKBD interaction similar to the trend observed
in our SPR data (Tables 1 and 3 and Fig. 5). Our N-Cbl
Y371 variants were classified into four categories, depend-
ing on the extent of LHR-TKBD perturbation observed
based on our SPR findings: complete (pTyr371-N-Cbl),
strongly-perturbing (Y371S, Y371D, Y371E), moderately
perturbing (Y371A, Y371H, Y371C), and non-perturbing
(Y371F). pTyr371-N-Cbl, which abolishes the LHR-
TKBD interaction, appears the most elongated, whereas
unphosphorylated, wild-type N-Cbl appears more com-
pact. Compared to wild-type N-Cbl, the strongly
Fig. 3 Comparison of crystal structure of N-Cbl (PDB 2Y1M) and
the model derived from iterative normal mode analysis. The
unphosphorylated, catalytically competent N-Cbl from the crystal
structure (PDB 2Y1M) is coloured cyan and is superposed with the
normal mode analysis-refined model. The TKBD is shown in blue, the
RING domain in orange and the LHR in yellow as a surface model
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perturbing mutants, N-Cbl Y371S, Y371E and Y371D,
are partially elongated (Rgs are 2.6, 2.7 and 2.7 nm, re-
spectively) but not as much as pTyr371-N-Cbl. Conform-
ational rearrangements of these mutants are also
confirmed by the corresponding Rflex values of approxi-
mately 84 %, 90 % and 88 % compared to approximately
60 % for wild-type N-Cbl. The moderately and non-
perturbing mutants have Rg and Dmax values more similar
to the wild-type N-Cbl, although with different degrees of
flexibility (Table 3 and Fig. 5). Notably, N-Cbl Y371F ap-
pears slightly more compact and less flexible than wild-
type N-Cbl, with an Rg of 2.38 nm, a Dmax of 7.67 nm, and
an Rflex of approximately 56 %. Together with SPR, these
data demonstrate that, in solution, RING domain accessi-
bility is connected to N-Cbl conformational rearrange-
ments induced by mutation or modification of Tyr371 in
the LHR.
The Tyr371-TKBD interaction appears to play a critical
role in mediating how elongated N-Cbl is in solution.
Fig. 4 Cartoon ensemble representation of pTyr371-N-Cbl. The TKBD domain is coloured blue. The predicted RING domain conformations are
shown in several colours as indicated in the table. The missing loops connecting the RING and TKBD domains are coloured according to the
corresponding RING domains but presented as transparent surfaces
Table 3 Average ensemble outcome Rg and Dmax from EOM 2.0
together with the χ value and the quantification of flexibility
(Rflex) for each N-Cbl variant
N-Cbl variant Rg (nm) Dmax (nm) Fit (χ value) Rflex (%)
Y371F 2.38 7.67 1.284 56
WT 2.41 7.89 0.831 60
Y368F 2.46 8.37 0.778 65
M222E 2.44 8.05 1.030 65
Y371H 2.44 8.24 0.695 69
Y371A 2.52 8.16 1.020 75
Y371S 2.61 8.89 0.774 84
Y371D 2.64 8.91 0.814 88
Y371E 2.79 9.43 0.773 90
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Although N-Cbl Y368F and M222E have higher binding
affinities for UbcH5B–Ub than wild-type, at SAXS reso-
lution both have characteristics comparable to wild-type,
suggesting they are similarly compact in solution. Al-
though N-Cbl M222E has a comparable binding affinity to
the strongly-perturbing N-Cbl Y371 mutants, in solution,
it appears more compact, as both Rg and Dmax are similar
to wild-type N-Cbl and flexibility is relatively limited
(Rflex ~60 %). N-Cbl Y368F has a higher binding affinity
for UbcH5B–Ub than wild-type, but at the level of
resolution provided by SAXS its characteristics and
compactness are similar to those of the wild-type pro-
tein, suggesting similar behaviour in solution.
Transformation potential of Cbl Y371 mutants in cells
To test the transforming potential of Cbl Y371 mutants
in cells, we performed focus formation assays using 3T3
cells stably transfected with N-terminally FLAG-tagged
Cbl variants. Relative protein expression levels of each
variant were assessed by immunoblotting (Fig. 6a). Foci
Fig. 5 EOM 2.0 analysis of N-Cbl Tyr371 mutants, N-Cbl Y368F and N-Cbl M222E. Mutants were clustered according to their ability to perturb the
LHR-TKBD interaction based on SAXS parameters shown in Table 3. a Strongly perturbing mutants. b Moderately perturbing mutants. c Weakly or
non-perturbing mutants
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were visualized with sulforhodamine B staining and
counted manually with a DNA Safe Imager (Invitrogen).
Afterwards, the sulforhodamine B stain was extracted
and the A564 measured to compare relative cell densities
[26, 27]. Foci counts and relative cell densities were ana-
lyzed by one-way ANOVA followed by Dunnett’s test
with wild-type Cbl as the control. Cbl70Z was included
among the variants tested as a positive transforming
control [22]. Other variants tested included the same set
used in our biochemical assays except in a full-length
context.
Foci were observed in cells transfected with Cbl Y371
mutants and Cbl70Z, but not in wild-type, Cbl Y368F-
or Cbl M222E-transfected cells (Fig. 6). When analyzed
by one-way ANOVA followed by Dunnett’s test, signifi-
cant differences (P < 0.05) in number of foci and cell
densities were observed between cells infected with wild-
type Cbl and all the Y371 mutants except Cbl Y371F
(Fig. 6c,d, Additional file 1: Figure S4). Significantly more
foci were present in Cbl70Z, Cbl Y371E and the MDS/
MPN Cbl Y371 mutant set and the relative cell density
was significantly greater compared to wild-type Cbl; how-
ever, there is no correlation between mutations that pro-
mote moderate or strong LHR-TKBD perturbations and
transformation potential. Based on the ability to form foci,
all the Cbl variants except Cbl Y368F and M222E have the
ability to potentiate transformation in cells. Based on
statistical analyses of the number of foci and relative cell
density, Cbl70Z, Cbl Y371E and the MDS/MPN Cbl Y371
mutant set have significantly higher numbers of foci than
wild-type Cbl. For Cbl Y371F, neither the number of foci
nor the relative cell density are significantly different than
in cells infected with wild-type Cbl; these results suggest
this mutant may potentiate transformation but not to the
same extent as the other Cbl Y371 mutants or Cbl70Z.
Discussion
In this work, we employed SAXS and SPR to characterize
how modifications and mutations in Cbl affect the con-
formation and accessibility of the RING domain in solu-
tion and subsequently investigate the relationship between
these characteristics and the ability of Cbl variants to
potentiate transformation in cells. Our results show that a
mutation (M222E) within the RING-TKBD interface
regulates accessibility of the RING domain only, whereas
mutation or modification of Tyr371 within the LHR medi-
ates the LHR-TKBD interaction, thereby regulating RING
domain accessibility as well as the space sampled by the
RING domain relative to the TKBD. The chemical nature
of the substitution or modification controls the LHR-
TKBD interaction and shifts the equilibrium between the
native conformation where the RING is restricted to the
Fig. 6 Transformation potential of Cbl variants in focus formation assays. a Immunoblot of lysates from 3T3 fibroblasts infected with FLAG-tagged
Cbl variants using α-FLAG antibody (top) and α-actin (bottom) antibody as a loading control. b Sulforhodamine B-stained 3T3 fibroblasts infected
with indicated Cbl variants. c Mean number of foci formed by Cbl variant-infected 3T3 fibroblasts shown in a bar graph (n = 3). No foci were
present in 3T3 cells infected with wild-type Cbl, Cbl M222E or Cbl Y368F. Double asterisks (**) denote significant differences (P < 0.05) between
indicated Cbl variant and wild-type using ANOVA followed by Dunnett’s multiple comparisons test. Error bars indicate standard deviation. d As in
(c) but for A564 of extracted sulforhodamine B from Cbl-infected 3T3 fibroblasts
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face of the TKBD opposing the substrate-binding site and
open conformations where the RING domain can access
other surfaces of the TKBD and potentially other regions
of Cbl. None of the Tyr371 mutants can adopt the
pTyr371 conformation that is critical for activation of
E2 ~ Ub and RTK ubiquitination, but all of the Tyr371
mutants perturb the LHR-TKBD conformation observed
in the native state except Cbl Y371F. Likewise, all of the
Tyr371 mutants except Cbl Y371F clearly potentiate
transformation in our focus formation assays, whereas Cbl
Y371F forms foci but statistical analyses of the number of
foci formed and relative cell densities suggest that this
mutant has less transformation potential than the others.
Previous studies have shown that Cbl Y371F is not trans-
forming in soft agar colony formation assays nor does it
promote tumour formation in nude mice [21, 22]. These
data indicate that the flexibility of the LHR features in the
Cbl Tyr371 mutant transformation mechanism.
Met222 is a key residue in maintaining the RING-
TKBD interaction in native Cbl. A Met to Glu mutation
was used to perturb this interaction and investigate the
importance of the RING-TKBD interaction on Cbl’s
conformation in solution. Our previous work and SPR
studies show that mutation of Met222 in the TKBD to
Glu increases Cbl’s E2–Ub binding affinity by approxi-
mately 8-fold and enhances Cbl’s in vitro autoubiquitina-
tion rate [6]. Though Cbl M222E has a higher binding
affinity for UbcH5B–Ub and is more active than wild-
type Cbl, SAXS analysis demonstrates that Cbl M222E
has parameters (Rg, Dmax and Rflex) comparable to wild-
type Cbl, suggesting both adopt a compact conformation.
In cells, Cbl M222E does not enhance EGFR ubiquitina-
tion (data not shown) nor does it potentiate transform-
ation in our focus formation assays. The lack of effect of
this mutant in these assays suggests structural regulation
of Cbl’s ligase activity requires more than a simple rotation
that exposes the E2-binding site on the RING domain.
Previous work has shown that phosphorylation of the
conserved LHR Tyr in the Cbl family enhances activity
in vitro and is essential for receptor PTK ubiquitination
in cells, where Cbl’s E3 ligase activity features promin-
ently in EGFR downregulation via lysosomal degradation
[8, 10, 11]. The rate and pattern of Cbl-mediated EGFR
ubiquitination determines whether EGFR is directed to
the lysosome or recycled to the membrane. X-ray crys-
tallography and NMR studies of Cbl and Cbl-b have
shown that this phosphorylation event eliminates RING-
mediated autoinhibition, optimally positions Ub for trans-
fer and juxtaposes the RING domain with the TKBD
substrate-binding site [6, 7, 9]. Notably, in the crystal
structures of Cbl and Cbl-b bound to Zap70 peptide and
E2 or E2 ~Ub, the conformations of RING domain rela-
tive to the TKBD are identical. Here, we show that, in
solution, when Tyr371 is phosphorylated, the Rg and Dmax
increase and EOM analysis demonstrates the linker region
becomes flexible, allowing the RING domain to sample
the space surrounding the TKBD rather than maintain the
crystallographically observed conformation. This is con-
sistent with other E3 ligases, where translational and
rotational movement of the RING domain are required
for Ub transfer to select substrate lysine sites (monoubi-
quitination and multiubiquitination) as well as polyUb
chain formation [28]. Cbl binds EGFR directly through its
TKBD and indirectly through growth factor receptor
binding 2-mediated interactions in the region C-terminal
to the RING domain [12]. Cbl-mediated ubiquitination of
EGFR is observed for both binding sites, highlighting a
potential essential role for RING flexibility in Cbl sub-
strate ubiquitination.
Our SAXS and SPR data show that mutations within
the LHR perturb the native LHR-TKBD conformation
and that the extent of perturbation is dependent on the
chemical nature of the amino acid substitution. In the
native state, Trp258, Ala262, Val263, and Met274 form a
hydrophobic pocket around the aromatic ring of Tyr371
and the side chain of Ser227 forms a hydrogen bond
with the hydroxyl group of Tyr371. The more disruptive
the mutation is to the hydrophobic environment, the
greater the perturbation in the LHR-TKBD interaction.
When Tyr371 is mutated to an amino acid with a
charged side chain like Asp or Glu or a small, polar side
chain like Ser, the UbcH5B–Ub binding affinity is approxi-
mately 8-fold enhanced compared to native Cbl and the
Rg and Dmax increase to values comparable to pTyr371-
Cbl. Additionally, SAXS analysis reveals these Tyr371
mutants are the most flexible compared to native Cbl.
Mutation of Tyr371 to smaller hydrophobic amino acids
like Cys or Ala only moderately perturbs the LHR-TKBD
interaction as evidenced by an approximately 2-fold en-
hancement in the UbcH5B–Ub binding affinity and the
moderate increase in Rg, Dmax and Rflex compared to na-
tive Cbl. Likewise, when Tyr371 is mutated to His, only
moderate to weak perturbation of the LHR-TKBD inter-
action occurs. There is an approximately 2-fold enhance-
ment in the UbcH5B–Ub binding affinity and SAXS
analysis shows evidence of more flexibility (slightly higher
values of Rg, Dmax and Rflex) compared to native Cbl.
When Tyr371 is mutated to Phe, the hydrophobic interac-
tions are not disturbed and the native state is maintained:
the UbcH5B–Ub binding affinity, Rg, Dmax and Rflex
values are comparable to native Cbl. In addition, previ-
ous in vitro autoubiquitination assays show native Cbl
and Cbl Y371F have comparable catalytic efficiencies
[6]. Thus, in solution, it appears as though Cbl Y371F
mimics the behaviour of native Cbl.
Mutation of Tyr371 is not the only site at which the
LHR-TKBD interaction can be perturbed. Our previous
work and current data show that mutation of Tyr368 to
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Phe also disrupts the LHR-TKDB interaction [6]. Cbl
Y368F binds UbcH5B–Ub approximately 2-fold more
tightly than native Cbl and has an approximately 2-fold
enhancement in catalytic efficiency for in vitro autoubi-
quitination. In addition, this mutant displays a slight
increase in all SAXS-based parameters (including Rflex)
compared to native Cbl. However, in contrast to the Cbl
Tyr371 mutants, Cbl Y368F does not promote focus
formation in our assays nor does it compromise EGFR
ubiquitination in cells [6] and previous work has also
shown this mutant does not form colonies in soft agar
assays nor promote tumour growth in nude mice [21, 22].
Though it is clear that Tyr368-TKBD interactions also
play a role in the conformations Cbl adopts in solution,
the significance of this interaction in Cbl’s ligase activity in
cells is unclear. Other studies have shown that Cbl ΔY368
is defective in EGFR ubiquitination and has the ability to
potentiate transformation in cells and in mice [21, 22]. In
addition, Cbl Y368C has also been identified in MDS/
MPN clinical samples, and, like Cbl Y371C and Y371S,
has been shown to potentiate transformation in cells and
in mice; however, whether PTK ubiquitination is compro-
mised remains unknown [19]. As observed for Tyr371, the
chemical nature of the mutation at Tyr368 might factor
into regulation of Cbl’s ligase activity as well as transform-
ation potential.
While the ability to ubiquitinate PTKs is essential for
Cbl-mediated downregulation of PTK signalling, previous
work has clearly shown that it is not the only prerequisite
for Cbl-dysfunction driven transformation. Thien et al.
[21] propose that the LHR-TKBD stability of Cbl mutants
contributes to their ability to potentiate transformation
based on the analysis of a number of linker region and
RING mutants: Cbl ΔY368, ΔY371 and Y371A promote
transformation but not Cbl Y368F or Y371F. Cbl Y368F is
slightly more flexible than native Cbl but retains the ability
to ubiquitinate receptor PTKs, whereas Cbl Y371F cannot
ubiquitinate receptor PTKs but is able to maintain the
native conformation in solution. Thus, it seems that both
characteristics contribute to the transformation potential
of Cbl mutants. Cbl functions as both an ubiquitin ligase
and adaptor in receptor PTK-mediated cell signalling.
Although enzymatic activity is slower in the absence of
Tyr371 phosphorylation, Cbl is still functional [6]. It may
be that when the LHR-TKBD interaction is perturbed, Cbl
ubiquitinates substrates that bind to regions other than
the canonical TKBD-binding site or the more flexible mu-
tants might ubiquitinate “dead end” lysines on substrates
such that biologically viable ubiquitination chains are not
formed. Alternatively, perturbed LHR-TKBD interactions
might disrupt oligomerization or interactions with other
proteins or lead to the non-sequential recruitment of
substrates to exposed surfaces that interfere with con-
trolled signalling.
Conclusions
We have shown that LHR-TKBD interactions regulate
Cbl’s ligase activity and conformations in solution. Mu-
tations or modifications within the LHR prevent Cbl from
maintaining a closed conformation where the RING do-
main is restricted to a surface opposite the TKBD-substrate
binding site; instead, depending on the nature of the
alteration, Cbl becomes flexible and the RING domain
can access multiple surfaces of the TKBD. Transformation
only occurs when mutations within the LHR (1) perturb
the native state and (2) fail to ubiquitinate PTKs.
Methods
Protein preparation
For crystallization, N-Cbl Y371F (residue 47–435) was
expressed, purified and stored as described previously
[6]. For SPR and SAXS analysis, N-Cbl variants were
cloned into a modified form of pGEX4T1 (GE Health-
care) containing an N-terminal histidine glutathione S-
transferase (His-GST) tag followed by a thrombin or
TEV-protease cleavage site and expressed in E. coli BL21
(DE3) Gold. pTyr371-N-Cbl was generated as described
previously [6]. For SPR analysis, all N-Cbl variants were
purified by Ni-NTA followed by glutathione-affinity chro-
matography. Anion exchange chromatography was subse-
quently used to separate His-GST-pTyr371-N-Cbl from
unphosphorylated His-GST-N-Cbl. For SAXS studies, N-
Cbl variants were then treated with TEV or thrombin
protease to cleave the His-GST tag and further purified by
Ni-NTA pass-back followed by anion exchange and size
exclusion chromatography. Proteins for SAXS were stored
in 25 mM Tris-HCl (pH 7.6), 500 mM NaCl and 1 mM
DTT at –80 °C. UbcH5B S22R C85K–Ub (referred to as
UbcH5B–Ub) was expressed, generated and purified as
described previously [7]. His-GST-tagged protein concen-
trations were determined by Bradford assay using BSA as
a standard and all other concentrations were determined
using a NanoVue Spectrophotometer (GE Healthcare).
Crystallization and structural determination
Crystals were obtained by mixing N-Cbl Y371F (10 mg/mL)
with an equal volume of reservoir solution containing
0.1 M Tris-HCl, pH 8.5, 3.0–3.1 M sodium formate,
and 5 mM DTT using hanging drop vapour diffusion at
8 °C. The crystals were flash-frozen in 0.1 M Tris-HCl,
pH 8.5, 3.0–3.1 M sodium formate, 5 mM DTT, 8 %
(v/v) glycerol, 8 % (v/v) ethylene glycol, and 8 % (v/v)
sucrose. Data were collected with beamline I04 at
Diamond Light Source, integrated with automated XDS
[29] and scaled using the CCP4 program suite [30]. Initial
phases were obtained by molecular replacement with
PHASER using native N-Cbl (PDB:2Y1M) [6]. N-Cbl
Y371F crystals belong to space group C2221 with six
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molecules in the asymmetric unit. The model was built in
COOT [31] and refined using PHENIX [32].
Biacore analysis
Cbl–UbcH5B–Ub binding experiments were conducted
as described previously [6, 23]. GST-Cbl variants were
coupled to CM-5 chips and binding was measured at a
concentration range of 0–120 μM of UbcH5B–Ub. The
data were analyzed using Biacore T200 Evaluation soft-
ware package (Biacore Life Sciences) and Scubber2.0c
(BioLogic Software).
Plasmids and cell culture
N-terminally FLAG-tagged Cbl variants were generated
by PCR amplification and ligation into a pBABE vector
[33] by In-Fusion (Clontech) according to the manufac-
turer’s instructions. Subsequently, these Cbl variants
were transiently transfected into Phoenix Eco cells using
Lipofectamine 2000 (Thermo Fisher Scientific) according
to the manufacturer’s instructions. Infection was per-
formed in 3T3 (mouse fibroblast) cells followed by puro-
mycin (2 μg/mL) selection. Cells were cultured in DMEM
containing 20 mM glutamine and 10 % donor bovine
serum in a 37 °C incubator at 5 % CO2.
Focus formation assays and sulforhodamine B extraction
To perform the focus formation assays, 3T3 cells were
seeded onto 10 cm2 dishes and infected with the Cbl
variants on the following day. This was followed by a
second round of infection after 24 hours and the media
changed on the following day. After 3 days of selection
with puromycin, the 3T3 cells were split and 0.5 × 105
cells seeded onto 3.5 cm2 dishes and cultured for 18 days
before being fixed in methanol and stained with sulfor-
hodamine B. Foci were then counted manually with a
DNA Safe Imager (Invitrogen). Afterwards, each dish
was incubated with 1.1 mL of 10 mM Tris, pH 10.5 for
5 minutes with rocking at room temperature to extract
sulforhodamine B and the absorbance of the extracted
dye was measured at 564 nm. Prism (Graph Pad, Mac
V5.0C) was used for statistical analyses (one-way ANOVA
followed by Dunnett multiple comparisons testing with
P < 0.05 treated as the cutoff for significant differences).
Immunoblotting
After 1 week, total protein was isolated from one 3.5 cm2
dish of each Cbl variant in whole cell lysis buffer contain-
ing 50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA,
1 % Igepal CA-630 (Sigma), and 10 % glycerol. Proteins
were separated under reducing conditions using SDS
polyacrylamide gel electrophoresis and transferred onto
a nitrocellulose membrane (GE Healthcare Life Sciences).
Blots were probed with rabbit anti-FLAG (Sigma Aldrich,
F7425) and goat anti-actin (SantaCruz Biotechnology,
sc-1616) antibodies, incubated with donkey anti-goat
IRDye 800CW and goat anti-rabbit IRDye 680LT sec-
ondary antibodies (LI-COR Biosciences, 925_32214 and
925_68021), and visualized using an Odyssey CLx Imaging
System (LI-COR Biosciences).
Small angle X-ray scattering
Synchrotron X-ray scattering data of Cbl mutants were
collected at EMBL P12 beamline (DESY, Hamburg) using
a robotic sample changer [34]. All the mutants were mea-
sured in the same buffer (500 mM NaCl, 25 mM Tris-HCl
(pH 7.6), 1 mM DTT) in a concentration series ranging
from either 0.5–10 mg/mL (0.5, 1, 2, 5, and 10 mg/mL) or
0.5–6.6 mg/mL (0.5, 1, 1.6, 3.3, and 6.6 mg/mL). SAXS
data were recorded at 10 °C using a PILATUS 2 M pixel
detector (DECTRIS, Baden, Switzerland) at a sample-
detector distance of 3.1 m and a wavelength of 0.15 nm.
This setup covers a range of momentum transfer of
0.1 < s < 5 nm–1 (s = 4π sin(θ)/λ, where 2θ is the scattering
angle). Initially, the data were pre-processed using an
automatic pipeline [35] and further analyzed using PRI-
MUS [36, 37]. The forward scattering I(0) as well as the Rg
were calculated using the Guinier approximation assum-
ing that, at very small angles (s < 1.3/Rg), the intensity is
represented as I(s) = I(0) · exp(-(sRg)
2/3) [38]. Linearity in
the Guinier region was used to exclude sample aggrega-
tion. The pair-distance distribution function P(r), from
which the Dmax and Rg were estimated, was computed
using GNOM [39]. Qualitative assessment of compactness
versus structural disorder was made by transforming the
scattering profiles in the so-called Kratky representation
[I(s)s2 vs. s] [40] and its normalized version [(sRg)
2*I(s)/I(0)
vs. sRg] [41]. The MM was derived from (1) the excluded
volume of the hydrated particle using the Porod invariant
[36] and (2) the excluded volumes of the ab initio models.
Ab initio models were created with DAMMIF [42] using
low resolution data (s < 2 nm–1). The algorithm constructs
bead models yielding a scattering profile with the lowest
possible discrepancy (χ) to the experimental data while
keeping beads interconnected and the model compact.
Twenty independent ab initio reconstructions were per-
formed for each Cbl mutant and then averaged using
DAMAVER [43]. Superimpositions between ab initio re-
constructions and available atomic models were made
using the software SUPCOMB [44]. The flexibility was
analyzed using EOM 2.0 [45] – an enhanced version of
the EOM [46], which assumes coexistence of a range of
conformations in solution for which an average scattering
intensity fits the experimental data. In EOM 2.0, a pool of
10,000 independent models is created as first step with
the aim to approximate the (otherwise infinite) conform-
ational space for a protein exhibiting disorder. For each
model in the pool the theoretical scattering curve is
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automatically computed with CRYSOL [47]. After-
wards, genetic algorithm (GA) is used to select ensembles
with varying numbers of conformers (usually from 5 to
40) by calculating the average theoretical profile and
fitting it to the experimental SAXS data. For each Cbl
mutant, the GA was repeated 100 independent times and
the ensemble with the lowest discrepancy reported as the
best solution out of 100 final ensembles. Furthermore, 100
repetitions of GA allowed the computation of Rg and Dmax
distributions so that structural information about the
flexibility could be extracted. Distributions with Rg average
values above the Rg average values calculated for the pool
are classified as extended whereas models with values
below the average as compact. The width of the distribu-
tion is also used to derive the flexibility of the particle,
whereby a narrow distribution indicates a rather rigid par-
ticle and broader distributions are associated with higher
flexibility [46]. Using EOM 2.0, systematic quantification
of the flexibility was made using the metric Rflex – which
computes the Shannon information entropy of the
distributions [45]. All the software used for the SAXS
data analysis belongs to the ATSAS 2.5 package [36].
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